Congratulations to our outstanding ML Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.
Our Director of Discovery and Platform, Dr. Thach Mai and CSO Dr. Jeremy O’Connell share more about Juvena’s discovery platform and approach to identifying and developing a regenerative biologics for promoting lung epithelium re-growth for the treatment of idiopathic pulmonary fibrosis at the IPF 2023 Annual summit.
Juvena is delighted to have had the opportunity to participate in the Mubadala Capital Singapore Forum. CEO Dr. Yousef was on the panel, “The New Frontier of Biotech Investing & Company Creation”
Juvena’s CSO, Dr. Jeremy O’Connell, and VP Dr. Mo Tabrizi attend and present our DM1 lead program at the annual Myotonic Dystrophy Foundation Conference which we are proud to sponsor
Juvena’s CSO, Dr. Jeremy O’Connell, and VP Dr. Mo Tabrizi attend and present, both through oral presentation and poster, our DM1 lead program at the annual Myotonic Dystrophy Foundation Conference which we are proud to sponsor
Our Director of Discovery and Platform, Dr. Thach Mai and CSO Dr. Jeremy O’Connell share more about Juvena’s discovery platform and approach to identifying and developing a regenerative biologics for promoting lung epithelium re-growth for the treatment of idiopathic pulmonary fibrosis at the IPF 2023 Annual summit.
Excited to announce Juvena’s CEO, Dr. Yousef’s participation at the Longevity Summit: Ending Age-Related Diseases in NYC on August 10-11! Join her and other experts as we revolutionize the field of aging research. Learn more and register here
